Key result
Quinidine therapy is linked to ~0% recurrence of polymorphic VT storms in CAD patients.
Why the study?
Following findings in patients during the healing phase of an acute coronary event, it was investigated whether CAD patients presenting with out-of-hospital polymorphic VT without a recent coronary event or obvious precipitating factor also respond to quinidine therapy.
Does quinidine therapy prevent recurrent polymorphic ventricular tachycardia in patients with coronary artery disease without acute ischaemia?
Population
20 CAD patients with unheralded, mainly out-of-hospital, polymorphic VT without acute myocardial ischaemia
Comparison
Quinidine therapy vs conventional antiarrhythmic therapy or no quinidine
Design
Retrospective study
Follow-up
Range 2 months to 11 years
Authors
Loading...
Quinidine may suppress polymorphic VT storms in stable CAD; hypothesis-generating and requires prospective confirmation before practice change.
Observational (n=20)
Does quinidine therapy prevent recurrent polymorphic ventricular tachycardia in patients with coronary artery disease without acute ischaemia?
Absolute Event Rate: 0% vs 15%
Quinidine is highly effective in suppressing refractory out-of-hospital polymorphic ventricular tachycardia in CAD patients without acute ischemia.
Viskin et al. (2019) conducted an observational in Coronary artery disease with out-of-hospital polymorphic ventricular tachycardia (n=20). Quinidine vs. No quinidine was evaluated on Recurrent polymorphic VT. Quinidine therapy invariably suppressed arrhythmic storms in CAD patients with out-of-hospital polymorphic VT, with 0% recurrences during long-term therapy versus 15% in those not receiving quinidine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: